| Literature DB >> 29376611 |
M V Epifanova1,2,3,4,5, M E Chalyi1,2,3,4,5, B R Gvasaliya1,2,3,4,5, I I Eremin1,2,3,4,5, A A Pulin1,2,3,4,5, I I Nadelyaeva1,2,3,4,5, S A Artemenko1,2,3,4,5, D A Galitskaya1,2,3,4,5, A M Repin1,2,3,4,5.
Abstract
Prostate cancer (PCa) is one of the most common maligmancies and causes of death among men. Radical prostatectomy (RP) is optimal and recommended treatment modality for localized prostate cancer. More than half of all men undergoing surgery experience problems with erectile function and existing treatments do not provide a positive effect. Thus, there is a need for new approaches to the restoration of erectile function in patients after RP. One of these is the use of cell technologies, namely the stromal-vascular fraction and autologous platelet-rich plasma. This review examines the results of preclinical and clinical studies investigating the efficacy and safety of these treatment options in erectile dysfunction.Entities:
Keywords: adipose tissue stem cells; autologous platelet-rich plasma; cell therapy; erectile dysfunction; mesenchymal stem cells; prostate cancer; radical prostatectomy; regenerative medicine; stem and regenerative adipose tissue cells; stem cells; stromal-vascular fraction
Mesh：
Year: 2017 PMID： 29376611
Source DB: PubMed Journal: Urologiia ISSN： 1728-2985